Skip to main content
. 2024 Dec 21;16:17588359241308389. doi: 10.1177/17588359241308389

Figure 3.

Figure 3.

Subgroup analysis of overall survival (a) and progression-free survival (b) in the liver metastasis and no liver metastasis groups.

AS, albumin-bound paclitaxel plus S-1; CPS, Combined Positive Score; MSI-H, microsatellite instability-high; MSI-L, microsatellite instability-low; MSS, microsatellite stable; PD-L1, programmed cell death ligand 1; SOX, S-1 plus oxaliplatin; WHO, World Health Organization; XELOX, capecitabine plus oxaliplatin.

*Both: Gastric body and the whole stomach and gastric antrum.